The European Commission has just imposed a fine of 462.6 million euros on the Israeli pharmaceutical group Teva for having abused its dominant position in order to delay competition to its flagship drug for the treatment of multiple sclerosis, Copaxone.
Brussels accuses the Israeli laboratory of having artificially extended patent protection for Copaxone and systematically disseminating misleading information on a competing product in order to hinder its entry into the market and its adoption.
Pascal Lemontel
|